NYSE: ABT
Abbott Laboratories Stock

ABT Price
$109.00
Fair Value Price
N/A
Market Cap
$192.80B
52 Week Low
$62.82
52 Week High
$111.29
P/E
62.29x
P/B
6.26x
P/S
5.16x
PEG
1.58x
Dividend Yield
1.25%
Revenue
$31.44B
Earnings
$3.11B
Gross Profit Margin
57.6%
Operating Margin
13.12%
Net Profit Margin
9.9%
Debt to Equity
1.23
Operating Cash Flow
$6B
Beta
0.95
Next Earnings
N/A
Ex-Dividend
Oct 14, 2020
Next Dividend
Nov 16, 2020

Zen Score

High
Medium
Low
41
Industry average

Reasons for this score

ABT ($109.00) is trading below its intrinsic value of $240.96, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
ABT is poor value based on its earnings relative to its share price (62.29x), compared to the US market average (42.6x)
Valuation
ABT is good value based on its earnings relative to its share price (62.29x), compared to the US Medical Devices industry average (83.05x)
Valuation

1 of 13

ABT News

Valuation

ABT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
62.29x
Industry
83.05x
Market
42.6x
ABT is poor value based on its earnings relative to its share price (62.29x), compared to the US market average (42.6x)
Valuation
ABT is good value based on its earnings relative to its share price (62.29x), compared to the US Medical Devices industry average (83.05x)
Valuation

ABT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.26x
Industry
10.32x
Market
62.61x
ABT is good value based on its book value relative to its share price (6.26x), compared to the US market average (62.61x)
Valuation
ABT is good value based on its book value relative to its share price (6.26x), compared to the US Medical Devices industry average (10.32x)
Valuation

ABT price to earnings growth (PEG)

For valuing profitable companies with growth potential
ABT is poor value relative to its rate of earnings growth, measured by PEG ratio (1.58x)
Valuation

ABT's financial health

Profit margin

Revenue
$7.7B
Net Income
$564.0M
Profit Margin
7.3%
ABT's Earnings (EBIT) of $4.13B can safely cover interest payments on company debt ($19.68B)
Financials
ABT's profit margin has increased (+0.5%) in the last year from (9.4%) to (9.9%)
Financials

Assets to liabilities

Assets
$66.8B
Liabilities
$36.4B
Debt to equity
0.6
ABT's short-term assets ($17.22B) exceed its short-term liabilities ($10.96B)
Financials
ABT's long-term liabilities ($27.02B) exceed its short-term assets ($17.22B)
Financials
ABT's debt has increased relative to shareholder equity (1.23), over the past 5 years ago (0.91)
Financials
ABT's debt to equity ratio (1.23) is considered high
Financials

Cash flow

Operating
$715.0M
Investing
-$393.0M
Financing
-$735.0M
ABT's operating cash flow ($6.40B) is sufficient to service the company's debt ($19.68B)
Financials

Abbott Laboratories Stock FAQ

(NYSE: ABT) Abbott Laboratories trades on the NYSE under the ticker symbol ABT. Abbott Laboratories stock quotes can also be displayed as NYSE: ABT.
(NYSE: ABT) Abbott Laboratories stock price per share is $109.00 today (as of Oct 26, 2020).
(NYSE: ABT) Abbott Laboratories's 52-week high was $111.29, and its 52-week low was $62.82. It is currently -2.06% from its 52-week high and 73.51% from its 52-week low.
(NYSE: ABT) Abbott Laboratories's market cap is $192.80B, as of Oct 27, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Abbott Laboratories's market cap is calculated by multiplying ABT's current stock price of $109.00 by ABT's total outstanding shares of 1768845326.
(NYSE: ABT) Abbott Laboratories currently has 1768845326 outstanding shares. With Abbott Laboratories stock trading at $109.00 per share, the total value of Abbott Laboratories stock (market capitalization) is $192.80B.

Abbott Laboratories stock was originally listed at a price of $32.75 in Dec 31, 1997. If you had invested in Abbott Laboratories stock at $32.75, your return over the last 22 years would have been 232.82%, for an annualized return of 5.62%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics